Curated Wealth Partners LLC Sells 12,757 Shares of Exelixis, Inc. $EXEL

Curated Wealth Partners LLC lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 63.0% in the third quarter, Holdings Channel.com reports. The firm owned 7,504 shares of the biotechnology company’s stock after selling 12,757 shares during the period. Curated Wealth Partners LLC’s holdings in Exelixis were worth $438,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of EXEL. Cassaday & Co Wealth Management LLC acquired a new position in shares of Exelixis in the 1st quarter valued at approximately $27,000. Western Wealth Management LLC purchased a new position in shares of Exelixis during the 1st quarter valued at approximately $29,000. Mather Group LLC. grew its position in shares of Exelixis by 124.6% during the third quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock worth $44,000 after buying an additional 420 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Exelixis during the second quarter worth approximately $46,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Exelixis during the second quarter worth approximately $57,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Mary Beckerle sold 9,812 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EXEL shares. HC Wainwright restated a “buy” rating and issued a $56.00 price target on shares of Exelixis in a research note on Thursday, July 2nd. Weiss Ratings upgraded shares of Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research note on Thursday, October 8th. Wells Fargo & Company raised their price objective on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Morgan Stanley raised their price objective on shares of Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a report on Thursday, July 23rd. Finally, BMO Capital Markets assumed coverage on shares of Exelixis in a research report on Tuesday, August 18th. They issued a “market perform” rating and a $54.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average price target of $50.79.

Exelixis Trading Down 1.0%

NASDAQ:EXEL opened at $62.23 on Friday. The stock has a 50 day moving average of $56.89 and a 200-day moving average of $52.88. The firm has a market capitalization of $15.42 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.76 and a beta of 0.47. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $63.39.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. As a group, analysts predict that Exelixis, Inc. will post 3.19 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.